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Guidelines fo r Vaccinating Pregnant Women
Abstracted from recommendations of the Advisory Committee on Immunization Practices (ACIP)
April 2013
“Risk to a developing fetus from vaccination o f the mother during pregnancy is theoretical. No 
evidence exists o f risk to the fetus from vaccinating pregnant women with inactivated virus or 
bacterial vaccines or toxoids. Live vaccines administered to a pregnant woman pose a theoretical 
risk to the fetus; therefore, live, attenuated virus and live bacterial vaccines generally are 
contraindicated during pregnancy.
“Benefits o f vaccinating pregnant women usually outweigh potential risks when the likelihood 
o f disease exposure is high, when infection would pose a risk to the mother or fetus, and when 
the vaccine is unlikely to cause harm.”
CDC. General recommendations on immunization: recommendations of the Advisory Committee
on Immunization Practices (ACIP). MMWR 2011; 60 (No. 2): 26.
The table on the following page may be used to find the general rule for vaccinating a 
pregnant woman with a particular vaccine.
4  The third column o f the table refers the reader to the page in this document where more 
specific information from the appropriate ACIP recommendations will be found.
E 'a c h  quotation from an ACIP recommendation in turn references the entire document, 
where the quotation(s) may be found in context.
Prenatal Screening
“Pregnant women should be evaluated for immunity to rubella and varicella and be tested for the presence of 
HBsAg during every pregnancy. Women susceptible to rubella and varicella should be vaccinated immediately 
after delivery. A woman found to be HBsAg positive should be monitored carefully to ensure that the infant 
receives HBIG and begins the hepatitis B vaccine series no later than 12 hours after birth and that the infant 
completes the recommended hepatitis B vaccine series on schedule.”
P assive Immunization during Pregnancy
“No known risk exists for the fetus from passive immunization o f pregnant women with immune globulin 
preparations.”
______________________CDC. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2011; 60 (No. 2): 27.
R o u tin e ly  R e c o m m e n d e d  V a c c in e s
For More Information 
See PageVaccine General Recommendation for Use in Pregnant Women
Hepatitis A Recommended if  otherwise indicated. 3
Hepatitis B Recommended in some circumstances. 3
Human Papillomavirus N ot recommended. 3
Influenza (Inactivated) Recommended. 3
Influenza (LAIV) Contraindicated. 3
M M R Contraindicated. 4
MCV4 (MenACWY) May be used if  otherwise indicated. 4
PCV13 Inadequate data for specific recommendation. 4
PPSV23 Inadequate data for specific recommendation. 4
Polio May be used if  needed. 5




T rave l a n d  O th e r  V a c c in e s
For More Information 
See PageVaccine General Recommendation for Use in Pregnant Women
Anthrax Low risk o f exposure -  not recommended. 
High risk o f exposure -  may be used.
6
BCG Contraindicated. 7
Japanese Encephalitis Inadequate data for specific recommendation. 7
MPSV4 May be used if  otherwise indicated. 7
Rabies May be used if  otherwise indicated. 7
Typhoid Inadequate data for specific recommendation. 7
Smallpox Pre-exposure -  contraindicated. 
Post-exposure -  recommended.
7
Yellow Fever May be used if  benefit outweighs risk. 8
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H e p a titis  A:
• [Hepatitis A] is an inactivated vaccine, and similar to hepatitis B vaccines, is recom m ended  
if  another high risk condition or other indication is presen t.1
H e p a titis  B:
• Pregnancy is not a contraindication to vaccination. Limited data suggest that developing 
fetuses are not at risk for adverse events when hepatitis B vaccine is administered to pregnant 
women. Available vaccines contain noninfectious HBsAg and should cause no risk of 
infection to the fetus.2
• Pregnant w om en w ho are identified as being at risk  for H B V  infection during pregnancy 
(e.g., having more than one sex partner during the previous 6 months, been evaluated or 
treated for an STD, recent or current injection drug use, or having had an HBsAg-positive sex 
partner) should be vaccinated .3
H u m an  P a p illo m a v iru s :
• H PV  vaccines are not recom m ended for use in pregnant w om en. If  a woman is found to 
be pregnant after initiating the vaccination series, the remainder o f the 3-dose series should be 
delayed until completion o f pregnancy. Pregnancy testing is not needed before vaccination. If 
a vaccine dose has been administered during pregnancy, no intervention is needed.4
• Patients and health-care providers should report any exposure to HPV4 [Gardasil] during 
pregnancy to M erck at telephone, 800-986-8999, and any exposure to HPV2 [Cervarix] 
during pregnancy to GlaxoSmithKline at telephone, 888-452-9622.4
In f lu e n z a  ( in a c tiv a te d ) :
• W omen in the second and third trimesters o f pregnancy are at increased risk for 
hospitalization from influenza. Because vaccinating against influenza before the season begins 
is critical, and because predicting exactly when the season will begin is impossible, routine  
influenza vaccination is recom m ended for all w om en w ho are or w ill be pregnant (in  any  
trim ester) during influenza season , which in the United States is usually early October 
through late M arch.5
In f lu e n z a  (LAIV):
• Do not adm inister L A IV  to . . . pregnant w om en .6
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M e a s le s , M u m p s, R u b e lla  (MMR):
• M easles-mumps-rubella (MMR) vaccine and its component vaccines should not be 
adm inistered to w om en know n to be pregnant. Because a risk to the fetus from 
administration o f these live virus vaccines cannot be excluded for theoretical reasons, women 
should be counseled to avoid becoming pregnant for 28 days after vaccination with measles or 
mumps vaccines or M M R or other rubella-containing vaccines.7
• Because o f the importance o f protecting women o f childbearing age against rubella and 
varicella, reasonable practices in any vaccination program include asking women if  they are 
pregnant or might become pregnant in the next 4 weeks; not vaccinating women who state 
that they are or plan to become pregnant; explaining the theoretical risk for the fetus o f MMR, 
varicella, or M M RV vaccine were administered to a woman who is pregnant; and counseling 
women who are vaccinated not to become pregnant during the 4 weeks after MMR, varicella, 
or M M RV vaccination. . . . Routine pregnancy testing o f women o f childbearing age before 
administering a live-virus vaccine is not recommended. If  a pregnant woman is inadvertently 
vaccinated or becomes pregnant within 4 weeks after M M R or varicella vaccination, she 
should be counseled about the theoretical basis o f concern for the fetus; however, M M R or 
varicella vaccination during pregnancy should not be considered a reason to terminate 
pregnancy.5
• Rubella-susceptible women who are not vaccinated because they state they are or may be 
pregnant should be counseled about the potential risk for CRS and the importance o f being 
vaccinated as soon as they are no longer pregnant.8
• A registry o f susceptible women vaccinated with rubella vaccine between 3 months before 
and 3 months after conception -  the "Vaccine in Pregnancy (VIP) Registry" -  was kept 
between 1971 and 1989. No evidence o f CRS occurred in the offspring o f the 226 women 
who received the current RA  27/3 rubella vaccine and continued their pregnancy to term .8
M e n in g o c o c c a l C o n ju g a te  (MCV4 / M enACW Y):
• Pregnancy should not preclude vaccination w ith M enA C W Y  . . ., if  indicated . W omen of 
childbearing age who become aware that they were pregnant at the time o f M enACW Y 
vaccination should contact their health-care provider or the vaccine manufacturer . . .9
P n e u m o c o c c a l  C o n ju g a te  (PCV 13):
• ACIP has not published pregnancy recommendations for PCV13 at this time. (Use o f PCV13 
is limited among women o f childbearing age.)
P n e u m o c o c c a l  P o ly s a c c h a r id e  (PPSV 23):
• The safety o f pneum ococcal polysaccharide vaccine during the first trim ester o f  
pregnancy has not been evaluated , although no adverse consequences have been reported 
among newborns whose mothers were inadvertently vaccinated during pregnancy.10
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P o lio  (IPV):
• Although no adverse effects o f IPV have been documented among pregnant women or their 
fetuses, vaccination o f pregnant w om en should be avoided on theoretical grounds .
However, if  a pregnant woman is at increased risk for infection and requires immediate 
protection against polio, IPV can be administered in accordance with the recommended 
schedules for adults.11
T e ta n u s , D ip h th e ria , a n d  P e r tu s s i s  (T d ap ); & T e ta n u s  a n d  D ip h th e ria  (Td) :
• Health-care personnel should adm inister a dose o f Tdap during each pregnancy
irrespective o f the patient’s prior history o f receiving Tdap. To maximize the maternal 
antibody response and passive antibody transfer to the infant, optim al tim ing for Tdap  
adm inistration is betw een 27 and 36 w eeks o f gestation although Tdap may be given at any 
time during pregnancy. 12
• For women not previously vaccinated with Tdap, if  Tdap is not administered during 
pregnancy, Tdap should be administered immediately postpartum.12
• Available data from . . . studies do not suggest any elevated frequency or unusual patterns of 
adverse events in pregnant women who received Tdap and that the few serious adverse events 
reported were unlikely to have been caused by the vaccine. 13
• Wound M anagement: If  a Td booster is indicated for a pregnant woman, health-care providers 
should administer Tdap.12
• Unknown or Incom plete Tetanus Vaccination: To ensure protection against maternal and 
neonatal tetanus, pregnant women who never have been vaccinated against tetanus should 
receive three vaccinations containing tetanus and reduced diphtheria toxoids. The recom­
mended schedule is 0, 4 weeks and 6 through 12 months. Tdap should replace 1 dose o f Td, 
preferably between 27 and 36 weeks gestation . . .12
• Providers are encouraged to report administration o f Tdap to a pregnant woman, regardless of 
trimester, to the appropriate manufacturer’s pregnancy registry: for Adacel® to sanofi pasteur, 
telephone 1-800-822-2463 and for Boostrix® to GlaxoSmithKline Biologicals, telephone 
1-888-825-5249.14
For more information about Tdap vaccine for pregnant women, see
http://www.cdc.gov/vaccines/vpd-vac/pertussis/tdap-pregnancy-hcp.htm.
V arice lla
• Because the effects o f the varicella virus on the fetus are unknown, pregnant w om en should  
not be vaccinated . Nonpregnant women who are vaccinated should avoid becoming pregnant 
for 1 month after each injection. For persons without evidence o f immunity, having a pregnant 
household member is not a contraindication for vaccination.15
5
• Wild-type varicella poses a low risk to the fetus. . . . Because the virulence o f the attenuated 
virus used in the vaccine is less that that o f the wild-type virus, the risk to the fetus, if  any, 
should be even low er.15
• Because o f the importance o f protecting women o f childbearing age against rubella and 
varicella, reasonable practices in any vaccination program include asking women if  they are 
pregnant or might become pregnant in the next 4 weeks; not vaccinating women who state 
that they are or plan to become pregnant; explaining the theoretical risk for the fetus o f MMR, 
varicella, or M M RV vaccine were administered to a woman who is pregnant; and counseling 
women who are vaccinated not to become pregnant during the 4 weeks after MMR, varicella, 
or M M RV vaccination. . . . Routine pregnancy testing o f women o f childbearing age before 
administering a live-virus vaccine is not recommended. If  a pregnant woman is inadvertently 
vaccinated or becomes pregnant within 4 weeks after M MR or varicella vaccination, she 
should be counseled about the theoretical basis o f concern for the fetus; however, M M R or 
varicella vaccination during pregnancy should not be considered a reason to terminate 
pregnancy.5
• Because pregnant women might be at higher risk for severe varicella and complications,
VZIG [Varicella Zoster Immune Globulin] should be strongly considered for pregnant women 
without evidence o f immunity who have been exposed. Administration o f VZIG to these 
women has not been found to prevent viremia, fetal infection, congenital varicella syndrome, 
or neonatal varicella. Thus, the primary indication for VZIG in pregnant women is to prevent 
complications o f varicella in the mother rather than to protect the fetus.15
• Any patient who receives VZIG to prevent varicella should receive varicella vaccine 
subsequently, provided the vaccine is not contraindicated. Varicella vaccination should be 
delayed until 5 months after VZIG administration.15
• In 1995, M erck and Co., Inc., in collaboration with CDC, established the VARIVAX 
Pregnancy Registry to monitor the maternal-fetal outcomes o f pregnant women who were 
inadvertently administered varicella vaccine 3 months before or at any time during pregnancy 
(to report, call: 1-800-986-8999).15
Z o s te r  (S h in g le s ) :
• Z oster vaccine is not recom m ended for use in pregnant w om en .16
• W omen should avoid becoming pregnant for 4 weeks following zoster vaccination. . . . If  a 
pregnant woman is vaccinated or becomes pregnant within 1 month o f vaccination, she should 
be counseled about potential effects on the fetus. 16
• In most circumstances, the decision to terminate a pregnancy should not be based on whether 
zoster vaccine was administered during pregnancy. M erck & Co., Inc., in collaboration with 
CDC, has established a pregnancy registry to monitor the maternal-fetal outcomes o f pregnant 
women who are inadvertently administered live-attenuated VZV-based vaccines within 1 
month o f pregnancy (telephone 800-986-8999). 16
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A n th ra x
• In a pre-event setting, in which the risk for exposure to aerosolized B . anthracis spores is 
presumably low, vaccination of pregnant w om en is not recom m ended and should be 
deferred until after pregnancy.17
• In a post-event setting that poses a high risk for exposure to aerosolized B. anthracis spores, 
pregnancy is neither a precaution nor a contraindication to PEP. Pregnant w om en at risk  for 
inhalation anthrax should receive A V A  and 60 days o f antimicrobial therapy as described.17
BCG
• B C G  vaccination should not be given during pregnancy . Even though no harmful effects 
o f BCG vaccination on the fetus have been observed, further studies are needed to prove its 
safety.18
J a p a n e s e  E n c e p h a li t is
• No controlled studies have assessed the safety, immunogenicity, or efficacy o f [Ixiaro] in 
pregnant women. Preclinical studies o f [Ixiaro] in pregnant rats did not show evidence of 
harm to the mother or fetus.19
M e n in g o c o c c a l P o ly s a c c h a r id e  (M PSV 4):
• Studies o f vaccination with MPSV4 during pregnancy have not documented adverse effects 
among either pregnant women or newborns. On the basis o f these data, pregnancy should  
not preclude vaccination w ith M PSV 4, if  indicated .20
R a b ie s :
• Because o f the potential consequences o f inadequately managed rabies exposure, pregnancy is 
not considered a contraindication to postexposure prophylaxis . Certain studies have 
indicated no increased incidence o f abortion, premature births, or fetal abnormalities 
associated with rabies vaccination. If  the risk o f exposure to rabies is substantial, pre­
exposure prophylaxis also m ight be indicated during pregnancy . Rabies exposure or the 
diagnosis o f rabies in the mother should not be regarded as reasons to terminate the 
pregnancy.21
T y p h o id :
• No data have been reported on the use o f any o f the . . . typhoid vaccines among pregnant
22women.
V a c c in ia  (S m allp o x ):
• Because o f the limited risk but severe consequences o f fetal infection, sm allpox vaccine  
should not be adm inistered in a pre-event setting to pregnant w om en or to w om en who  
are trying to becom e pregnant.23
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• Before vaccination, women o f childbearing age should be asked if  they are pregnant or intend 
to become pregnant in the next 4 weeks; women who respond positively should not be
vaccinated. 23
• If  a pregnant woman is inadvertently vaccinated or if  she becomes pregnant within 4 weeks 
after smallpox vaccination, she should be counseled regarding concern for the fetus.
Smallpox vaccination during pregnancy should not ordinarily be a reason to terminate 
pregnancy. CDC has established a pregnancy registry to prospectively follow the outcome of 
such pregnancies and facilitate the investigation o f any adverse pregnancy outcome among 
pregnant women who were inadvertently vaccinated. For enrollment in the registry, contact 
CDC at 404-639-8253.23
• Pregnant women w ho have had a definite exposure to sm allpox virus (i.e., face-to-face, 
household, or close-proximity contact with a smallpox patient) and are, therefore, at high risk 
for contracting the disease, should . . . be vaccinated. Smallpox infection among pregnant 
women has been reported to result in a more severe infection than among nonpregnant 
women. Therefore the risks to the mother and fetus from experiencing clinical smallpox 
substantially outweigh any potential risks regarding vaccination. In addition, vaccinia virus 
has not been documented to be teratogenic, and the incidence o f fetal vaccinia is low.23
• W hen the level o f  exposure risk is undeterm ined , the decision to vaccinate should be made 
after assessment by the clinician and the patient o f the potential risks versus the benefits of 
smallpox vaccination. 24
Y ellow  F ev er:
• Pregnancy is a precaution for Y F vaccine adm in istration , compared with most other live 
vaccines, which are contraindicated in pregnancy. If  travel is unavoidable, and the risks for 
YFV exposure are felt to outweigh the vaccination risks, a pregnant woman should be 
vaccinated. If  the risks for vaccination are felt to outweigh the risks for YFV exposure, 
pregnant women should be issued a medical waiver to fulfill health regulations.25
• Because pregnancy might affect immunologic function, serologic testing to document an 
immune response to the vaccine should be considered.25
• Although no specific data are available, a woman should wait 4 weeks after receiving YF 
vaccine before conceiving.25
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Formulating policy to guide vaccination o f women during pregnancy and breastfeeding is 
challenging because the evidence-base to guide decisions is extremely limited. In 2008, CDC 
published G uiding P rinciples fo r  D eveloping A C IP  R ecom m endations fo r  Vaccination D uring  
P regnancy and  B reastfeeding  to “provide guidance to help standardize both the process of 
policy formulation and the format and language o f recommendations for pregnant and 
breastfeeding women” to CDC workgroups or subject matter experts developing vaccine 
statements subsequent to that date. This document can be found online at 
http://www.cdc.gov/vaccines/recs/acip/downloads/preg-principles05-01-08.pdf.
Principles for Developing Pregnancy Recom m endations
B re a s tf e e d in g  a n d  V a c c in a tio n
“N either inactivated nor live-virus vaccines adm inistered to a lactating w om an affect the  
safety o f breastfeeding for w om en or their in fan ts . Although live viruses in vaccines can 
replicate in vaccine recipients (i.e., the mother), the majority o f live viruses in vaccines have 
been demonstrated not to be excreted in human milk. Varicella vaccine virus has not been found 
in human milk. Although rubella vaccine virus might be excreted in human milk, the virus 
usually does not infect the infant. If  infection does occur, it is well tolerated because the virus is 
attenuated. Inactivated, recombinant, subunit, polysaccharide, and conjugate vaccines, as well as 
toxoids, pose no risk for mothers who are breastfeeding or for their infants.
“B reastfeeding is a contraindication for sm allpox vaccination of the mother because o f the 
theoretical risk for contact transmission from mother to infant. Y ellow  fever vaccine should be 
avoided in breastfeeding w om en . However, when nursing mothers cannot avoid or postpone 
travel to areas endemic for yellow fever in which risk for acquisition is high, these women 
should be vaccinated.”
CDC. General recommendations on immunization: recommendations of the Advisory Committee
on Immunization Practices (ACIP). MMWR 2011; 60 (No. 2): 26.
Note: The information in this booklet reflects the ACIP’s recommendations on vaccinating 
pregnant or nursing women. Information contained in the vaccine manufacturers’ package inserts 
may differ. Package inserts can be found online at http://www.immunize.org/fda/.
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F D A  P r e g n a n c y  C a t e g o r i e s
Regulation requires that each product be classified under one of five pregnancy categories, on the basis o f risk of 
reproductive and developmental adverse effects or, for certain categories, on the basis o f such risk weighted against 
potential benefits. These categories are:
Pregnancy Category A. Adequate and well controlled studies in women fail to demonstrate a risk to the fetus in the 
first trimester (and there is no evidence o f a risk in later trimester), and the possibility o f fetal harm appears remote.
Pregnancy Category B . Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no 
adequate and well-controlled studies in pregnant women O R  Animal studies have shown an adverse effect, but 
adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus during the first 
trimester (and there is no evidence o f risk in later trimesters).
Pregnancy Category C . Animal reproduction studies have shown an adverse effect on the fetus and there are no 
adequate and well-controlled studies in humans, but potential benefits may warrant use o f the drug in pregnant 
women despite potential risks O R  Animal reproduction studies have not been conducted and there are no adequate 
and well-controlled studies in humans.
Pregnancy Category D. There is positive evidence o f human fetal risk based on adverse reaction data from 
investigational or marketing experience or studies in humans, but potential benefits may warrant use o f the drug in 
pregnant women despite potential risks.
Pregnancy Category X. Studies in animals or humans have demonstrated fetal abnormalities and/or there is 
positive evidence o f human fetal risk based on adverse reaction data from investigational or marketing experience, 
and the risks involved in the use o f the drug in pregnant women clearly outweigh potential benefits.
For most vaccines there is a shortage o f well-controlled studies, while experience has shown a very favorable 
risk/benefit ratio. FDA pregnancy categories for vaccines licensed in the U.S. (from the appropriate manufacturers’ 
package inserts) are as follows:
Pregnancy Category B: Human Papillomavirus, Influenza (Fluzone Intradermal, Fluarix, FluLaval, 
Agriflu, Afluria, Flublok, Flucelvax), Japanese Encephalitis (Ixiaro), Meningococcal (Menveo), Tdap 
(Boostrix).
Pregnancy Category C: Hepatitis A, Hepatitis B, Influenza (Fluzone, Fluzone High Dose, Fluvirin, 
FluMist), MMR, Meningococcal (Menactra, Menomune), Pneumococcal, Polio, Td, Tdap (Adacel), 
Varicella, Zoster, BCG, Rabies, Typhoid, Yellow Fever.
Pregnancy Category D: Anthrax, Vaccinia.
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